Overview

Evaluation of Thiosulfate in End Stage Renal Disease and Kidney Transplantation

Status:
Enrolling by invitation
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
Kidneys retrieved from deceased donors will be randomized for conventional perfusion (University of Wisconsin: UW) with or without supplementation of thiosulfate, a major H2S metabolite, and transpl anted thereafter. Recipient's renal function will be assessed prospectively to determine if thiosulfate improves allograft function.
Phase:
Phase 1
Details
Lead Sponsor:
Lawson Health Research Institute
Treatments:
Pharmaceutical Solutions
Sodium thiosulfate